Intrinsiqq
IDEXX Laboratories, Inc. logo

IDEXX Laboratories, Inc. Quality Score

IDXX

⊜ Compare
Quality80

Business quality remains strong (avg 98/100), but valuation is pulling the composite down (avg 40/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
47.1x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
40/100
42.2x

Above 30x, cash flow yield is thin

Revenue Growth
70/100
8.5%

5–10% CAGR, steady but not exceptional

Cash Flow Growth
100/100
34.9%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
100/100
-6.6%

Shrinking >2%, active buybacks

Margin Trend
100/100
+5.6pp

Expanded 3+pp, strong improvement

Capital Structure
90/100
$301M

Net debt/FCF of 0.2x, easily serviceable

2022
$113M
$891M
2023
$454M
$817M
2024
$288M
$737M
2025
$180M
$578M
TTM
$198M
$499M
CashDebt
Return on Capital
100/100
54.5%

Above 20%, exceptional capital efficiency

Customize WeightsPremiumUpgrade

IDEXX Laboratories (IDXX) quality: score, margins and returns

IDEXX Laboratories (IDXX) scores 80/100 on Intrinsiqq's quality score (a high-quality business), a weighted blend of 8 metrics each scored 0 to 100, on 32.4% operating margins and 54.5% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is IDEXX Laboratories (IDXX) a high-quality business?+

IDEXX Laboratories scores 80 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a high-quality business on these measures. Recent figures include a 32.4% operating margin and a 54.5% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does IDEXX Laboratories's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from IDXX's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where IDEXX Laboratories scores well and where it falls behind.

What is IDEXX Laboratories's return on invested capital (ROIC)?+

IDEXX Laboratories earns about 54.5% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to IDXX's margins and growth on this scorecard to judge durability.

How profitable is IDEXX Laboratories?+

IDEXX Laboratories runs an operating margin of about 32.4% and a net margin of about 25.4%. Revenue has grown at roughly 9.7% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 28 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 3 Nov 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

In Vitro & In Vivo Diagnostic Substances · Pick stocks to compare with IDXX

CompareIntrinsic value
QDELQuidelOrtho Corporation
$14.35+1.85%0
LNTHLantheus Holdings, Inc.
$101.14+0.34%92
NEOGNeogen Corporation
$12.45+2.89%15
MYGNMyriad Genetics Inc.
$6.02-0.33%23
JAZZJazz Pharmaceuticals plc
$234.66+2.14%58
ELANElanco Animal Health Incorporated
$25.31+3.01%46
PRGOPerrigo Company plc
$15.83+0.83%17
ALNYAlnylam Pharmaceuticals Inc
$161.08+0.74%81

Held by ETFs

IDXX is in 338 US ETFs. The largest of them, with IDXX's weight in each:

Spot a number that looks wrong? Check it in IDXX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IDXX

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.